Longevity Labs Ventures

longevity.vc

VCMatch tracks Longevity Labs Ventures as an investor focused on Biotech and Pharma companies and Silicon Valley and Boston markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Not specified

Focus Areas

Biotech, Pharma

Geography

Silicon Valley and Boston

Investment Thesis

The firm invests to accelerate development of longevity medicines by backing mission-oriented, founder-led biotech companies that can get drugs for age-related diseases into human trials and ultimately increase healthy human lifespan. They believe longevity is a new industry inside biotech that requires unconventional, often first-time founders, novel regulatory and fundraising approaches, and long time horizons — and that clinical proof in humans will unlock mainstream talent and capital.

Is Longevity Labs Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Longevity Labs Ventures is most relevant for founders raising venture-backed rounds in Biotech and Pharma, especially across Silicon Valley and Boston.

Focus statement

Invests in early-stage, founder-led companies working on interventions to increase healthy human lifespan (longevity/age-related disease therapeutics), with emphasis on founders who are mission-driven and willing to build new regulatory, scientific, and company-building paradigms.

Value Add

Explicitly targets longevity as a distinct industry within biotech rather than treating it like a conventional disease area.
Preference for mission-oriented, often first-time or unconventional founders: “You have to *truly care about the field *to build a longevity company–this kind of person is not going to be a CEO for hire.”
Track record and operational programs: ran an accelerator (started 2018) and branded subsequent fund age1, and claims to have funded early longevity companies that went public and advanced drug candidates into patients.
Thesis that clinical proof in humans is the key inflection point to attract mainstream pharma talent and capital — invests to produce those pivotal clinical results.
Willingness to tolerate novel regulatory and fundraising strategies because the field requires new approaches that traditional biotech playbooks don’t cover.